THOMAS VALENTE: Open Payments
NPI 1467416511 · LEESBURG, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$270,227 in 435 payments from 18 companies in 2025. Trend: 2023 $188,365 · 2024 $156,480 · 2025 $270,227
Speaker / faculty: $210,171Consulting: $31,690Travel & lodging: $13,333Food & beverage: $10,634Honoraria: $4,400
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 104 | $71,655 |
| E.R. Squibb & Sons, L.L.C. | 82 | $56,308 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 73 | $48,134 |
| Otsuka America Pharmaceutical, Inc. | 44 | $35,251 |
| Teva Pharmaceuticals USA, Inc. | 43 | $27,365 |
| Alkermes, Inc. | 29 | $11,134 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 12 | $8,348 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 7 | $5,420 |
| Luye Pharma (USA) Ltd. | 10 | $4,402 |
| Janssen Pharmaceuticals, Inc | 7 | $1,480 |
Products named: INGREZZA, COBENFY, CAPLYTA, REXULTI, AUSTEDO XR, ABILIFY MAINTENA, UZEDY, LYBALVI.
Industry payments across FL — which companies pay providers there.
